The trial, sponsored by the University of Padova, investigates the comparative effects of two basal insulin analogues, detemir and glargine, on endothelial function in poorly controlled type 2 diabetes patients with macroangiopathy. Given the increasing prevalence of diabetes and its cardiovascular complications, successful outcomes could enhance the therapeutic profile of these insulin formulations, potentially leading to expanded market opportunities. The findings may influence treatment guidelines and provide a competitive edge in the diabetes management market, particularly for patients with cardiovascular comorbidities. Companies with existing insulin products may need to assess their positioning in light of these results, especially if one formulation demonstrates superior efficacy in improving EPC levels and endothelial function.